Sareum Holdings Plc

Sareum Holdings Plc SAR

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Sareum Holdings Plc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Sareum Holdings Plc
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Sareum Holdings Plc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Sareum Holdings Plc dividends.
Year Amount Change
2006 0.0p
2007 0.0p
0%
2008 0.0p
0%
2009 0.0p
0%
2010 0.0p
0%
2011 0.0p
0%
2012 0.0p
0%
2013 0.0p
0%
2014 0.0p
0%
2015 0.0p
0%
2016 0.0p
0%
2017 0.0p
0%
2018 0.0p
0%
2019 0.0p
0%
2020 0.0p
0%
2021 Sign Up Required

Sareum Holdings Plc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 25 September 2021
52 Week Low
0.0% on 25 September 2021
Next Ex-Div-Date Countdown
Sign Up Required

About Sareum Holdings Plc

Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.

Sector
Pharmaceuticals & Biotechnology
Country
United Kingdom
Share Price
£0.07 (yesterday's closing price)
Shares in Issue
3,370 million
Market Cap
£219mn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
No articles found